The Goodwin capital markets practice regularly advises on follow-on offerings, secondary sales, block trades and liability management transactions, with a focus on aligning each financing with a company’s capital structure, shareholder profile and long-term growth strategy. Beyond traditional IPOs, the team is active in alternative financing structures, including at-the-market programs and PIPE transactions. The practice is led by Edwin O’Connor in New York, alongside Bradley Weber in Silicon Valley and James Barri in Boston. O’Connor has particular experience advising on capital markets transactions in the life sciences, technology and clean tech sectors. Weber is recognised for his strength in complex securities law matters and sophisticated transactional issues. Barrie adds further depth to the bench, advising issuers and underwriters on a range of equity capital markets transactions. Bryan Quinn departed the firm in July 2025.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Testimonials
Collated independently by Legal 500 research team.
‘Strengths are their industry knowledge and deep experience in healthcare and life sciences.’
‘They are commercial, reasonable and have market leading industry knowledge of their clients and of the healthcare landscape.’
Key clients
- Septerna
- Prime Medicine
- Amylyx Pharmaceuticals
- Sionna Therapeutics
- Akero Therapeutics
- Altimmune, Inc.
- Wisdomtree, Inc.
- Disc Medicine
- Applied Intuition
- Underwriters - American Healthcare REIT
- BXP, Inc.
- FountainVest Partners
Work highlights
Advised Akero Therapeutics in its $402.5 million follow-on offering.
Advised Upstream Bio on its $293 million initial public offering.
Advised the Underwriters on the $772.8 million American Healthcare REIT.
Practice head
Edwin O'Connor; Bradley Weber; James Barri